1 March 2024 - Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with other therapy according to medical instructions.

After sales of the drug to statutory health insurance exceeded 30 million Euros in the previous 12 calendar months, Immunocore submitted a dossier to assess the additional benefits of tebentafusp when compared to the appropriate comparator therapy.

Read IQWiG press release